Effective and evidence-bas…, …ON-CL3-2027-01-FCT-05

Effective and evidence-based responses to the increased availability and use of synthetic drugs and stimulants in Europe

Announced, not yet open · HORIZON Innovation Actions · HORIZON-CL3-2027-01-FCT-05

Next cut-off

04 Nov '27

in 424 days

Per grant

€4.0M

the call's own average

Grants expected

projects that will be funded

Funding rate

70%

the rest is your own money

Expected Outcome:

Project results are expected to contribute to all of the following expected outcomes:

Evidence base is improved for effective prevention, treatment and harm reduction of synthetic drugs and stimulants in Europe;
Relevant European security practitioners, notably Police Authorities, Civil Society Organisations and Non-Governmental Organisations, are equipped with skills, tools and technology aimed at reducing the violence and offences associated with use and marketing of these substances, as well as at combatting drug trafficking from its origin to destination (i.e., through the entire supply chain);
Increased understanding of relevant European security practitioners and policymakers regarding the influence of external drivers of change of societal, technological, legal, economic and ethical nature to the availability and use of different types of synthetic drugs and drug markets.

Scope:

This topic asks for proposals that seek to develop effective and evidence-based responses to the growing prevalence of synthetic drugs and stimulants, such as cocaine and crack cocaine, within the EU. As these substances increasingly influence the drug landscape, the urgent need for enhanced understanding and strategies in their prevention, treatment, and harm reduction has never been clearer. Amongst other, there is also a lack of pharmacological data for the emerging drugs, needed to do proper risk assessments and interventions of these drugs in Europe. Key focus areas include:

Evidence-based approaches, strengthening the evidence base to inform effective prevention strategies, treatment modalities, and harm reduction practices targeted at synthetic drugs and stimulants. This includes identifying best practices in current interventions and evaluating their efficacy.

Trimmed here, the full scope, expected outcomes and award criteria are on the official topic page ↗.

What applying costs you

Item	Estimate	Note
Drafting effort	6–8 weeks	single submission
Partner search	4–8 weeks	runs in parallel, and it is the part that slips
Your own money	€1.7M	30% of project cost, over the project's life
Time to first payment	6–9 months	cut-off → evaluation → grant agreement

Item

Estimate

Note

Drafting effort

6–8 weeks

single submission

Partner search

4–8 weeks

runs in parallel, and it is the part that slips

Your own money

€1.7M

30% of project cost, over the project's life

Time to first payment

6–9 months

cut-off → evaluation → grant agreement

These are Bemzu's estimates from the call's structure (the number of stages and whether a consortium is required) not figures published by the Commission. Only the co-financing share is read from the call itself.

Where these conditions come from

Two kinds of row. Most are the sentence we read the condition from, quoted out of the call itself. Some say plainly that they are not a quotation but the programme's own rule for this type of action, the EU portal publishes a table of contents where the conditions should be, so for a Research and Innovation Action the rate comes from the rulebook rather than from the fiche.

Condition	Quoted from the call, or the rule behind it
Consortium size	Not quoted from this call — Innovation Actions under the Horizon Europe rules are at least three independent legal entities from three different Member States or Associated Countries, at least one established in a Member State.
Funding rate	Not quoted from this call — Innovation Actions under the Horizon Europe rules are funded at 70% of eligible costs for profit-making organisations, and 100% for non-profit legal entities — the rate shown here is the one that applies to a company.
Maturity	null Activities are expected to achieve TRL 6-8 by the end of the project – see General Annex B.

Condition

Quoted from the call, or the rule behind it

Consortium size

Not quoted from this call — Innovation Actions under the Horizon Europe rules are at least three independent legal entities from three different Member States or Associated Countries, at least one established in a Member State.

Funding rate

Not quoted from this call — Innovation Actions under the Horizon Europe rules are funded at 70% of eligible costs for profit-making organisations, and 100% for non-profit legal entities — the rate shown here is the one that applies to a company.

Maturity

null Activities are expected to achieve TRL 6-8 by the end of the project – see General Annex B.

Effective and evidence-based responses to the increased availability and use of synthetic drugs and stimulants in Europe

In context of Horizon Europe

What this call funds

What applying costs you

Where these conditions come from

Also open in HE

Become the beneficiary.